Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGF2BP1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
IGF2BP1 siRNA (or knockdown) refers to small interfering RNA molecules designed to specifically target and silence the expression of Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), an oncofetal RNA-binding protein and m6A reader. In research settings, IGF2BP1 knockdown is widely utilized to investigate the role of IGF2BP1 in promoting tumor cell proliferation, invasion, metastasis, and chemoresistance across various cancers, including uterine sarcoma, breast cancer, and hepatocellular carcinoma. Silencing IGF2BP1 has been shown to downregulate oncogenic targets such as c-Myc and ABCB1 (MDR1), thereby sensitizing cancer cells to chemotherapeutic agents like doxorubicin.
- Other names
- IGF2BP1 knockdownIGF-2BP1 knockdownIGF 2BP1 knockdownIMP-1 siRNAIMP1 siRNAIMP 1 siRNAsi-IGF2BP1si-IGF-2BP1si-IGF 2BP1siIGF2BP1siIGF-2BP1siIGF 2BP1
02
Targets
IGF2BP1ABCB1 (P-glycoprotein)MYC (MYC proto-oncogene protein)
Beyond the preview
Go deeper on IGF2BP1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGF2BP1 siRNA.